Cancer Genetics and Epigenetics 2024, Vol.12, No.3, 125-136 http://medscipublisher.com/index.php/cge 128 technological advancements, integrated knowledge bases, expanded target identification, increased availability of MTBs, and enhanced navigation tools for physicians. These measures aim to streamline the pathway from molecular diagnostics to effective clinical trial matching, ultimately improving patient outcomes in precision medicine. 4 Integration of GWAS Findings into Clinical Practice 4.1 Translational research Translational research bridges the gap between genome-wide association studies (GWAS) and clinical applications, enabling the identification of genetic variants that can be targeted for precision treatment in liver cancer. Recent advancements in next-generation sequencing (NGS) and GWAS have facilitated the discovery of numerous genetic mutations associated with liver cancer, such as those in the Wnt/β-catenin pathway, TP53/cell-cycle pathways, and telomere maintenance (Nakagawa et al., 2019). These findings have been instrumental in developing targeted therapies and improving patient outcomes. For instance, the I-PREDICT study demonstrated the feasibility of using tumor DNA sequencing to recommend individualized combination therapies, resulting in improved disease control and survival rates1. Similarly, the integration of molecular profiling into clinical practice has shown promise in identifying actionable mutations and guiding personalized treatment plans (Malone et al., 2020). 4.2 Personalized treatment plans Personalized treatment plans based on GWAS findings involve tailoring therapies to the genetic profile of individual patients. This approach has shown significant potential in improving treatment efficacy and patient outcomes. For example, a study on refractory metastatic solid tumor patients in China utilized comprehensive NGS testing to guide matched therapies, resulting in a notable proportion of patients achieving complete or partial remission (Wang, 2019). Additionally, the use of molecular tumor boards to discuss treatment recommendations based on genetic data has proven effective in optimizing therapy for patients with complex genetic profiles (Kato et al., 2020). The identification of biomarkers predictive of drug efficacy and tolerability through GWAS and NGS has further enhanced the ability to develop personalized treatment plans for liver cancer patients (Di Paolo et al., 2019). 4.3 Clinical implementation The clinical implementation of GWAS findings involves several challenges, including the interpretation of complex genetic data and the integration of these findings into routine clinical practice. Despite these challenges, significant progress has been made in recent years. For instance, the establishment of multidisciplinary molecular tumor boards has facilitated the translation of genetic data into actionable treatment recommendations, leading to improved patient outcomes. Moreover, the development of bioinformatics tools and guidelines by regulatory authorities has supported the incorporation of genetic testing into clinical trials and routine practice (Di Paolo et al., 2019). The use of single-cell analysis and other advanced molecular characterization techniques has also provided deeper insights into tumor heterogeneity and resistance mechanisms, further enhancing the clinical implementation of precision medicine in liver cancer (Figure 2) (Heinrich et al., 2020). In conclusion, the integration of GWAS findings into clinical practice has the potential to revolutionize the treatment of liver cancer by enabling personalized and targeted therapies. Continued advancements in translational research, personalized treatment plans, and clinical implementation will be crucial in realizing the full potential of precision medicine for liver cancer patients (Sicklick et al., 2019). Heinrich et al. (2020) found that single-cell analysis of the tumor immune environment in hepatocellular carcinoma (HCC) patients provides valuable insights into immune cell heterogeneity and dynamics. Through transcriptomic profiling, researchers can identify distinct immune subgroups and processes such as T cell clonality and trajectory. This approach also helps distinguish between various activation and exhaustion states of immune cells. By comparing tumor-infiltrating immune cells with those from non-tumorous sites, researchers can uncover organ-specific immune cell characteristics and understand the tumor's influence on its microenvironment. Additionally, this analysis facilitates the identification of functional suggestions, survival analyses, and subgroup
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==